1. Aesthetic chills modulate reward learning in anhedonic depression.
- Author
-
Jain A, Schoeller F, Esfand S, Duda J, Null K, Reggente N, Pizzagalli DA, and Maes P
- Abstract
Objective: This study aimed to examine the potential of experiencing aesthetic chills to enhance reward learning in individuals with elevated depressive symptoms, specifically anhedonia, by investigating the effect of chills on participants' ability to modulate behavior as a function of rewards., Methods: A total of 103 participants with elevated depressive symptoms took part in the experiment. Among them, 59 participants had depressive symptoms (BDI ≥ 20), with 26 classified as "High Anhedonic" (HA) and 33 as "Low Anhedonic" (LA). Additionally, 39 participants without elevated depressive symptoms (BDI < 20 and SHAPs <32) were included as the control group. We utilized ChillsDB, an open-source database of validated audiovisual stimuli known to elicit chills in the US population., Results: Anhedonic participants who experienced chills demonstrated a significant increase in response bias (p = .004) towards rewards compared to those who did not experience chills. Highlighting specificity, no significant difference in reward bias was observed among LA participants., Conclusions: These findings suggest that the experience of chills has the potential to impact reward learning in anhedonic individuals, aligning with the known neurobiology of this phenomenon. These results highlight the potential of aesthetic chills as a novel approach to elicit and enhance positive affect in depressed populations., Competing Interests: Declaration of competing interest Dr. Schoeller is the co-founder of BeSound SAS and Nested Minds LTD, holds ownership shares and has received compensation from both companies. Over the past 3 years, Dr. Pizzagalli has received consulting fees from Boehringer Ingelheim, Compass Pathways, Engrail Therapeutics, Neumora Therapeutics (formerly BlackThorn Therapeutics), Neurocrine Biosciences, Neuroscience Software, Otsuka, Sunovion, Sage Therapeutics, Sama Therapeutics, and Takeda; he has received honoraria from the American Psychological Association, Psychonomic Society and Springer (for editorial work) and from Alkermes; he has received research funding from the Brain and Behavior Research Foundation, BIRD Foundation, the Dana Foundation, DARPA, Millennium Pharmaceuticals, NIMH, and Wellcome Leap MCPsych; he has received stock options from Compass Pathways, Engrail Therapeutics, Neumora Therapeutics, and Neuroscience Software; he has a financial interest in Neumora Therapeutics, which has licensed the copyright to the probabilistic reward task through Harvard University. Dr. Pizzagalli's interests were reviewed and are managed by McLean Hospital and Partners HealthCare in accordance with their conflict of interest policies. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. All other authors have no conflicts of interest or relevant disclosures., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF